Meunier M, Thepot S, Nimubona S, Veloso M, Lefebvre T, Karim Z, Ropert-Bouchet M, Garban F, Amé S, Reynes C, Salanoubat C, Parinet V, Laribi K, Eftekhari P, Delaunay J, Venton G, Santana C, Cheze S, Dimicoli-Salazar S, Toma A, Molimard M, Fenaux P, Rolland-Neyret V, David-Tchouda S, Park S. Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study. Haematologica; https://doi.org/10.3324/haematol.2026.301420 [Early view].